New Weight-Loss drug combo tested in early trial
NCT ID NCT07245771
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called RN3161, alone and combined with the weight-loss drug tirzepatide, in 104 adults with overweight or obesity. The main goals are to check safety and how the body handles the drug. Researchers will also measure weight changes. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RN3161 (investigational drug) and tirzepatide
What this could lead to
If successful, this could lead to a new weight-loss treatment option for people with overweight or obesity, possibly more effective when combined with existing drugs.
What could go wrong
This is an early-phase trial with only 104 participants, so results may not apply to everyone. The drug could cause side effects or fail to show meaningful weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Pty Ltd
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••